$PULM IPO'ed last week via Reverse Merger into a Nasdaq shell.  While company is clinical stage biotech, it is fully funded ($27 Million in Cash and Equivalents) which should carry the company for another 2 yrs, has a strong management team, and most importantly, is funded heavily by Polaris Partners - a very successful multi billion dollar VC fund.  If they're backing the company this heavily, one can assume they've done their due diligence and feel strongly about appreciation.  Rule #1 - Follow the smart money.

Since the company is new, but not relegated to a quiet period, I would expect the news to start to flow consistently.  Press releases which had no reason to be disseminated as a private company will now be put out to the public. 

Just last week they released big news on Development program with Mylan, announced the first inhaled anti fungal therapy for Cystic Fibrosis, and added a Polaris Partner to the BOD. 

From a technical perspective, the chart is a dream for entry. 

The stock is in a clear cut uptrend as evidenced by the trendlines.  After the post merger explosion the stock quickly peaked at $14.50 and since retraced right back to the low trendline.  As witnessed by the chart, this is the bounce area.  First target on a successful bounce looks to be $11.75 which served as support last week and may provide overhead resistance here.  Above that it goes straight to $12.75 which was the peak.  If that breaks, the $14.50 recent high would be next likely target. 

The effective float is 1.9 Million shares.  This float can be cornered in a day if the right fund gets behind it.